MTC categories | Using PrEP group | Not using PrEP group | Pooled incidence RR (95% CI) | |||||
Estimates* (n) | PYs followed* | Pooled incidence per 100 PYs (95% CI) | I2 (%) | PYs followed | Pooled incidence per 100 PYs (95% CI) | I2 (%) | ||
Total | 13 | 24 720 | 1.27 (0.68 to 2.36) | 96.30 | 17 210 | 3.08 (2.15 to 4.40) | 92.70 | 0.45 (0.31 to 0.67) |
Good (≥80%) | 3 | 5435 | 0.60 (0.42 to 0.84) | 0.00 | 5438 | 2.83 (1.59 to 4.99) | 88.90 | 0.28 (0.19 to 0.41) |
Moderate (60%~80%) | 3 | 9959 | 0.65 (0.35 to 1.21) | 80.10 | 6197 | 1.61 (0.59 to 4.35) | 94.10 | 0.42 (0.29 to 0.62) |
Poor (<60%) | 5 | 8843 | 2.80 (1.31 to 5.90) | 96.70 | 5111 | 4.15 (3.39 to 5.07) | 52.70 | 0.75 (0.45 to 1.25) |
*Because one study might have different study drug type (eg, TDF and/or TDF/FTC), there were 13 independent PrEP efficacy estimates and 11 estimates for both MTC and protective efficacy in the 10 included studies.
MTC, medicine-taking compliance; PrEP, pre-exposure prophylaxis; PYs, person years; RR, risk ratio; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.